Mibefradil offers a novel mechanism of calcium channel antagonism with potential benefits for hypertension by avoiding reflex sympathetic activation.
Answers are grounded in this paper and cite their sources.
May support T-type calcium channel blockade in hypertension; leaves open outcome trials versus standard agents.
Properties of mibefradil Mibefradil produces a unique combination of T-type Ca2+ channel block and protein kinase C inhibition, and thus effective vasodilation, without adverse positive chronotropic or negative inotropic cardiac actions. Lack of reflex sympathetic activation In contrast to virtually every other vasodilator, mibefradil avoids the reflex sympathetic activation and increased heart rate that form the practical limit for existing vasodilator action. The freedom from increased heart rate is especially important for maintaining an adequate blood flow in the coronary circulation. Conclusions Mibefradil offers a new concept in Ca2+ channel antagonism, with long-term protection against the pathophysiological consequences of hypertension.
No takes yet. Share an insight, caveat, or question.
Hermsmeyer et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: